RESEARCH ARTICLE

JENER Journal of Empirical and Non-Empirical Research
Volume 2, Issue 3, Page 495-499 | Article No. 70
DOI: 10.4898/jener.v2i3.a70
ISSN: 7895-9216
Journal homepage: https://jenerjournal.com
Journal email: editor@jenerjournal.com

JENER Journal
JENER Journal of Empirical and Non-Empirical Research

Disorders of the Hypothalamic-Pituitary-Ovarian Axis in Gynecology: A Focus on Key Neuroendocrine Syndromes

Saravanan Madhumitha[1], Kizhakarahouse Manojkumar Kavitasrhee[2], Mahalingam Senthil Kumar Sri Varshni[3] & Aidarbek kyzy Aidanek[4]

[1,2,3]Students, Osh State University, International Medical Faculty, Osh, Kyrgyzstan .
[4]Lecturer, Department of Gynecology, Osh State University, International Medical Faculty, Osh, Kyrgyzstan.

ARTICLE INFORMATION

Article history:
Published: March 2026

Keywords:
Hypothalamic-pituitary-ovarian axis
Asherman syndrome
Galactorrhea-amenorrhea
Adrenogenital syndrome
Secondary amenorrhea

ABSTRACT

Menstrual irregularities and amenorrhea are common gynecological manifestations that are frequently caused by intricate disruptions in the hypothalamic-pituitary-ovarian axis or abnormalities in the reproductive outflow tract. This article aims to give a comprehensive scientific overview of four different syndromes that are traditionally associated with reproductive system dysfunction. These syndromes include Asherman syndrome, Galactorrhea-Amenorrhea syndrome, Sheehan syndrome, and Adrenogenital syndrome. While Galactorrhea-Amenorrhea syndrome, Sheehan syndrome, and Adrenogenital syndrome are traditionally examples of primary neuroendocrine and endocrine disorders caused by dysfunction in prolactin regulation, pituitary necrosis, and adrenal enzyme abnormalities, respectively, Asherman syndrome is an anatomical abnormality in the endometrium that presents with secondary amenorrhea and mimics an endocrine disorder. By critically discussing the definitions, etiologies, pathophysiology, clinical manifestations, diagnostic methods, and treatment strategies for all four syndromes, this review aims to provide clinicians with a systematic approach to differentiating and treating these intricate gynecological disorders. Accurate diagnosis requires an intricate approach to patient presentation with hormonal level determination and imaging/endoscopic techniques to restore reproductive health and prevent long-term sequelae in different body systems.

1. Introduction

The regular human female reproductive cycle is regulated by the complex and highly coordinated neuroendocrine interactions in the hypothalamic-pituitary-ovarian axis, culminating in the regular shedding of the functional endometrium. Any disruption in the axis at any level, such as hypothalamic gonadotropin-releasing hormone pulsatility and end-organ endometrial responsiveness, leads to menstrual disorders in the form of amenorrhea or oligomenorrhea, often in concert with infertility.

Gynecological endocrinology often presents with symptomatology that requires pinpointing the exact location of the endocrine disruption. Galactorrhea-amenorrhea syndrome and Sheehan syndrome represent disorders in the central neuroendocrine axis affecting the anterior pituitary. Adrenogenital syndrome represents disorders in the peripheral endocrine axis affecting the HPO axis. Asherman syndrome represents disorders in the end-organ axis affecting the endometrium. This article attempts to dissect these four syndromes in detail to understand their distinct etiopathogenetic processes and clinical courses to help in the rational approach to their management.

2. Methodology

2.1 Asherman Syndrome

Definition

Asherman Syndrome (AS) is an acquired abnormality of the uterus in which there is the formation of adhesions in the uterine cavity, which can be partial or complete, involving the uterine cavity and/or cervical canal. AS is not a neuroendocrine disorder in the true sense, as it is a structural failure of an end organ causing amenorrhea in the presence of normal neuroendocrine function.

Causes

The main cause of Asherman syndrome is trauma to the basalis layer of the endometrium. This is most commonly due to:

- Surgical Trauma: Dilatation and curettage (D & C) due to retained products of conception, incomplete miscarriage, or elective termination of pregnancy. The risk is significantly increased when D & C is performed in the postpartum or post-abortal period when the uterus is soft and highly vascularized.
- Infections: Severe pelvic inflammatory disease (PID) or genital tuberculosis, especially in the context of developing countries.
- Other Uterine Surgeries: Hysteroscopic myomectomy, polypectomy, or complex cesarean sections.

Pathophysiology

The human endometrium has a functional layer, which is shed during menstruation, and a basal layer, which Regenerates the functional layer. In Asherman syndrome, trauma, which may be caused by infection, destroys the basal layer. The absence of the regenerative cells of the basalis prevents the opposing walls of the myometrium from separating, thus forming fibrotic tissue bridges between them, called synechiae. The absence of the functional layer means that the normal proliferative response of the endometrium to ovarian estrogen and progesterone levels does not occur, thus causing uterine factor amenorrhea.

Clinical Features

- Menstrual Abnormalities: Secondary amenorrhea, hypomenorrhea, or oligomenorrhea.
- Infertility and Obstetric Complications: Primary or secondary infertility; recurrent miscarriages; abnormal placentation (placenta accreta spectrum), if pregnancy occurs.
- Pain: Cyclic pelvic pain (hematometra), if functional endometrium is present behind a cervical or lower uterine structural occlusion.

Diagnosis

- Hormonal Profile: Normal levels of basal FSH, LH, estradiol, and prolactin.
- Progestin Challenge Test: Negative – absence of withdrawal bleeding; and subsequently, an estrogen-progestin challenge test is also usually negative.
- Imaging/Endoscopy:
  - Hysteroscopy: The gold standard investigation – simultaneous treatment also possible.
  - Hysterosalpingography (HSG) / Sonohysterography: Shows filling defects, cavity narrowing, and obliteration.

Differential diagnosis

Premature ovarian insufficiency (POI), polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, and cervical stenosis.

Management

- Surgical: Hysteroscopic adhesiolysis (resection of synechiae with scissors or minimal electro cautery) to restore normal anatomy.
- Postoperative Adhesion Prevention: Placement of a Foley catheter balloon, intrauterine device (IUD), or hyaluronic acid anti-adhesion barriers in the uterus for a brief period.
- Hormonal Therapy: Postoperative high-dose exogenous estrogen (with subsequent progestin) therapy for 30-60 days to allow rapid re-epithelialization of the denuded uterine walls.

2.2 GALACTORRHEA- AMENORRHEA SYNDROME

Definition

Galactorrhea-amenorrhea syndrome, as a neuroendocrine symptom complex, consists of the abnormal discharge of milk from the breasts (galactorrhea) accompanied by the absence of menstruation (amenorrhea), which has absolutely no relation to pregnancy or the postpartum state. This syndrome is caused almost entirely by pathological hyperprolactinemia.

Causes

- Pituitary Adenomas: Prolactinomas (microadenomas <10mm, macroadenomas >10mm) are the most common cause.
- Pharmacological: Dopamine receptor antagonists (eg., typically/atypical antipsychotics, antiemetics like metoclopramide) and prolactin-stimulating drugs (eg., SSRIs, verapamil).
- Hypothyroidism: Primary hypothyroidism leads to elevated Thyrotropin- Releasing Hormone (TRH), which concurrently Stimulates lactotrophs to secrete prolactin.
- Hypothalamic/Stalk Lesions: Tumors (craniopharyngiomas), trauma, or infiltration diseases that compress the pituitary stalk, disrupting the normal inhibitory flow of hypothalamic dopamine.

Pathophysiology

The secretion of prolactin from the anterior pituitary lactotroph cells is under the unique control of tonic inhibition from hypothalamic dopamine. Any condition that causes increased production of prolactin (adenomas) or disrupts the tonic inhibition of hypothalamic dopamine (stalk compression, medications) causes hyperprolactinemia. The increased levels of prolactin have a direct inhibitory effect on hypothalamic GnRH pulsatility. The decreased GnRH pulsatility causes decreased pituitary secretion of FSH and LH, causing anovulation, hypoestrogenism, and amenorrhea. At the same time, the increased prolactin stimulates the mammary gland's alveolar cells to initiate.

Clinical features

- Gynecological: Secondary amenorrhea or oligomenorrhea, infertility, vaginal dryness, and dyspareunia, all due to hypoestrogenism.
- Breast: Milky discharge from one or both nipples, which may be spontaneous or expressible.
- Neurological (when macroadenoma is suspected): Bitemporal hemianopsia due to compression of the optic chiasm, headaches.
- Metabolic: Long-term hypoestrogenism increases the risk of osteopenia/osteoporosis.

Diagnosis

- Laboratory Tests: Prolactin is significantly increased (usually >100 ng/mL in prolactin adenomas; >200 Ng/mL is suggestive of macroadenomas). Thyroid screen (TSH, free T4) to exclude hypothyroidism. hCG to exclude pregnancy. FSH, LH, estradiol (usually low or low Normal).
- Imaging: Magnetic Resonance Imaging (MRI) of the brain with gadolinium enhancement, with particular emphasis on the sella turcica, which may reveal pituitary tumors.

Differential diagnosis

Pregnancy (the most common cause of amenorrhea with galactorrhea), breast diseases (intraductal papilloma, which causes a bloody discharge), polycystic ovary syndrome (can have mild hyperprolactinemia), and chronic kidney disease (reduced prolactin clearance).

Management

- Medical: Dopamine agonists are the first line of treatment. Cabergoline, which is given Once or twice a week, is preferred over Bromocriptine because it is more effective and has a more favorable side-effect profile. These drugs cause tumor shrinkage and promptly normalize ovulatory cycles.
- Surgical: Transsphenoidal adenomectomy is reserved for those who do not respond to or cannot tolerate dopamine agonists, or in those with rapidly expanding macroadenomas causing acute visual loss.
- Thyroid Replacement: If primary hypothyroidism is the cause, levothyroxine normalizes TRH, prolactin, and menses.

2.3 Sheehan's Syndrome (S. Shihana)

Definition

Sheehan's syndrome, historically occasionally mentioned in older texts with variant spellings, such as "S. Shihana," is postpartum hypopituitarism resulting from ischemic necrosis of the anterior pituitary gland. This is a critical neuroendocrine emergency resulting from massive postpartum hemorrhage and hypovolemic shock.

Causes

The singular underlying cause is severe, life-threatening postpartum hemorrhage (PPH) or profound systemic hypotension during or immediately following childbirth.

Pathophysiology

Under normal circumstances, the anterior pituitary shows considerable physiological hypertrophy and hyperplasia due to elevated estrogen levels. In fact, the anterior pituitary almost doubles in size. However, the blood supply does not increase proportionately. This renders the pituitary gland extremely susceptible to ischemia. In cases of massive PPH, severe hypotension results in vasospasm and thrombosis in the low-pressure hypothalamic-pituitary portal vessels. This causes coagulative necrosis of the anterior pituitary cells. Depending upon the extent of necrosis, patients may lose the ability to secrete Prolactin, FSH, LH, Growth Hormone (GH), ACTH, and TSH. The posterior pituitary is spared due to its direct arterial blood supply.

Clinical features

- Immediate Postpartum: The inability to lactate (agalactia) is often the first and most classic symptom and is usually caused by absolute prolactin deficiency.
- Gynecological: Amenorrhea (inability to resume menstrual periods after delivery), genital shrinkage, and loss of axillary and pubic hair.
- Endocrine Systemic:
  - Secondary Hypothyroidism: Fatigue, intolerance of cold, weight gain, constipation.
  - Secondary Adrenal Insufficiency: Lethargy, weakness, hypoglycemia, hypotension (without hyperpigmentation, as this is a deficiency in ACTH).
  - Severe: May manifest as an adrenocortical crisis with coma or hyponatremia.

Diagnosis

- Laboratory Profile: Panhypopituitarism is evident.
  - Low basal hormones: Free T4, cortisol, estradiol, and IGF-1.
  - Inappropriately low or normal trophic hormones: TSH, ACTH, FSH, LH, Prolactin.
- Dynamic Testing: Insulin tolerance test or Cosyntropin (ACTH) stimulation test to establish secondary adrenal insufficiency.
- Imaging: MRI of the pituitary. In the acute phase, it may show an enlarged but unenhancing pituitary. In the chronic phase, months to years later, it characteristically shows an "empty sella," a shrunken, fibrotic remnant of the pituitary.

Differential diagnosis

Lymphocytic hypophysitis (autoimmune, usually occurs late in pregnancy or early postpartum), pituitary apoplexy (hemorrhage into a pre-existing adenoma), and severe postpartum depression (which may mimic the fatigue of hypothyroidism).

Management

Management of hormone replacement therapy is a lifelong physiological process.

- Glucocorticoids: These must be replaced first to avoid an acute adrenal crisis if thyroid hormones are given later. Hydrocortisone or prednisone is used.
- Thyroid Hormones: Levothyroxine, and this is monitored by clinical status and Free T4, while TSH is not reliable in this case.
- Gonadal Steroids: Estrogen-progestin replacement therapy is needed to maintain bone density, cardiovascular health, and sexual function and is replaced until natural menopause.
- Growth Hormone: This is replaced in patients to improve body composition and quality of life.

2.4 ADRENOGENITAL SYNDROME (CONGENITAL ADRENAL HYPERPLASIA - CAH)

Definition

Adrenogenital syndrome is a set of autosomal recessive neuroendocrine/metabolic disorders that are all known as Congenital Adrenal Hyperplasia (CAH). Adrenogenital syndrome is defined as deficiencies in specific enzymes in the process of adrenal steroidogenesis that results in the overproduction of adrenal androgens and has a profound effect on the female reproductive system.

Causes

21-Hydroxylase (CYP21A2) Deficiency: Accounts for >95% of cases.
11β-Hydroxyzine Deficiency: Accounts for most of the remaining cases (features hypertension).
Rare variants: 3β-hydroxysteroid dehydrogenase Deficiency, 17α-hydroxylase deficiency.

Pathophysiology

For example, in the classic case of 21-hydroxylase deficiency, the enzyme is necessary for the metabolism of progesterone into cortisol and aldosterone. The absence of this enzyme causes the following effects:

- Reduced Cortisol: The absence of cortisol removes the feedback inhibition on the hypothalamus and pituitary glands. This causes a massive and continuous hypersecretion of ACTH.
- Adrenal Hyperplasia: The constant hypersecretion of ACTH causes hyperplasia of the bilateral adrenal cortex.
- Shunting of the Enzymatic Pathway: The absence of the ability to produce cortisol from the precursors (such as 17-hydroxyprogesterone) causes the enzymatic pathway to be diverted entirely to the production of androgens (androstenedione and testosterone). These extremely high levels of androgens cause virilization and strongly suppress the hypothalamic GnRH pacemaker, leading to amenorrhea and anovulation.

Clinical features

Classic Form (Severe): This condition manifests at birth. Females have ambiguous genitalia (clitoral enlargement and fusion of the labia).This condition may present with life-threatening salt-wasting (hyponatremia, hyperkalemia, hypovolemia) due to the concomitant deficiency of aldosterone.

Non-Classical Form (Late-Onset): This condition manifests in peripubertal or adult females. This condition is characterized by severe hyperandrogenism (hirsutism, severe acne, male pattern baldness), amenorrhea, oligomenorrhea, and infertility. Genitalia at birth are normal.

Diagnosis

- Biochemical: The diagnostic marker for this condition is a high level of 17-hydroxyprogesterone (17-OHP). High levels of DHEA-S, androstenedione, and testosterone.
- Dynamic Testing: The ACTH (Cosyntropin) stimulation test confirms the high level of 17-OHP.
- Genetics: Genetic testing for mutations in the CYP21A2 gene confirms the diagnosis.
- Imaging: Ultrasound examination of the pelvic area usually shows normal female internal organs (uterus and ovaries), distinguishing this condition from other disorders of Sex Development (DSD). Adrenal CT scan may show bilateral hyperplasia.

Differential diagnosis

The major differential diagnosis for non-classic CAH is Polycystic Ovary Syndrome (PCOS), as both are associated with hyperandrogenism and oligo/amenorrhea. Other differential diagnoses include androgen-producing tumors, both adrenal and ovarian, which are characterized by the rapid onset of virilization and Cushing's syndrome.

Management

- Glucocorticoid Replacement: The Mainstay of Treatment. The exogenous administration of glucocorticoids (hydrocortisone, dexamethasone) not only replaces the missing cortisol but, importantly, also provides negative feedback inhibition to stop the overproduction of androgens by the adrenal glands.
- Mineralocorticoid Replacement: Fludrocortisone and salt tablets are given to individuals with the salt-wasting phenotype.
- Gynecological Management: After the administration of glucocorticoids, androgens are suppressed, and the HPO axis normalizes, resulting in the return of normal ovulatory menses. Anti-androgens like spironolactone and oral contraceptives may be added for symptomatic control of hirsutism.
- Surgical: Feminizing genitoplasty in infancy or later in life for classic CAH patients with ambiguous genitalia.

3. Discussion

The differential diagnosis for amenorrhea and dysfunction in the female reproductive system demands a comprehensive knowledge of the various compartments of the female reproductive system. The four syndromes discussed here are examples of disruptions at different pathophysiological nodes.

Asherman syndrome is an isolated uterine (Compartment 1) dysfunction. The hormonal background is completely normal; hence, there are no neuroendocrine complications. The only concern is to correct the structural problems. At the other end of the spectrum are Galactorrhea-Amenorrhea and Sheehan's syndromes, both involving the pituitary (Compartment 3). While the prolactinoma secretes hormones that physiologically inhibit the HPO axis, Sheehan's syndrome is due to ischemia, completely destroying the function of the pituitary gland. While the former is easily managed with dopamine agonists, the latter requires immediate and lifelong hormone replacement to prevent life-threatening adrenal crisis.

The adrenogenital syndrome, also known as CAH, represents a complex peripheral inter-axis cross-reaction. Here, the defect in the HPO axis occurs in the adrenal gland, but the androgen produced chemically suppresses the HPO axis in the hypothalamus. The problem in diagnosing between non-classic CAH and PCOS, due to their similar clinical features, has made this a real problem in endocrinology. Hence, it becomes essential to measure the levels of 17-OHP in any woman with hyperandrogenism and amenorrhea. The general algorithm for the evaluation of these cases begins with the exclusion of pregnancy and the determination of TSH, PRL, FSH, and LH. In cases with normal hormonal profiles, a structural evaluation may be necessary, especially in cases with previous instrumentation, suggesting Asherman syndrome. However, abnormal hormonal profiles point to neuroimaging, such as MRI in cases of prolactinomas or empty sella syndrome, or specific biochemical tests for the evaluation of neuroendocrine or enzymatic defects.

4. Conclusion

The neuroendocrine and structural syndromes in gynecology include a broad range of etiologies, from iatrogenic trauma (Asherman syndrome), neoplastic growth (Galactorrhea-amenorrhea), to obstetric vascular catastrophes (Sheehan's syndrome) and enzymatic defects (Adrenogenital syndrome). In spite of the common clinical features of amenorrhea and infertility, the pathophysiological causes are vastly different. A highly structured, stepwise, and systematic approach to diagnosis, based on clinical evaluation, neuroendocrine investigations, and sophisticated imaging modalities, is crucial to the management of neuroendocrine and structural syndromes in gynecology. Appropriate therapeutic interventions, ranging from surgical and medical management to hormone replacement therapy, can lead to a significant improvement in the quality of life for the afflicted women.

References

[1] Zaraq khan. Etiology, Risk Factors,and Management of Asherman syndrome.Obstet Gynecol. Sep,2023;142(3).P:543-554. https://doi.org/10.1097/aog.0000000000005309

[2] Charles M March. Asherman's syndrome. Semin Reprod Med. Mar,2011; 29(2).P:83-94.https://doi.org/10.1055/s-0031-1272470

[3] María Pardo-Figuerez, Carlos Simon, Xavier Santamaria. Asherman syndrome at single-cell resolution. Am J Obstet Gynecol. Apr,2025; 232(4S).P:S148-S159.10.https://doi.org/10.1016/j.ajog.2024.12.023

[4] Eva Dreisler, Jens Joergen Kjer. Asherman's syndrome:current perspectives on diagnosis and management. Int J Women's Health. Mar, 2019;11.P: 191-198.https://doi.org/10.2147/IJWH.S165474

[5] Alessandro Conforti, Carlos Alviggi, Antonio Mollo,et Al. The management of Asherman syndrome: a review of literature. Reprod Biol Endocrinol. Dec,2013;11:118.https://doi.org/10.1186/1477-7827-11-118

[6] Shivaprasad,C. Sheehan's syndrome Newer advances.Indian Journal of Endocrinology and Metabolism.Sep, 2011;15Suppl 3(Suppl3):P S203-S207. https://doi.org/10.4103/2230-8210.84869

[7] Erin Keely, Janine Malcolm. Congenital adrenal hyperplasia in pregnancy: approach depends on who is the 'patient'. Obstet Med.Sep,2012;5(4).P:154-160.https://doi.org/10.1258/om.2012.120015

[8] Phyllis W Speiser, Ricardo Azziz, Laurence S Baskin, et Al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Sep,2010;95(9): P:4133-60.

[9] A Nordenström,S Ahmed, et Al. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm Res.Dec,2005;63(1).P: 22-28.https://doi.org/10.1159/000082896

[10] Magnetometer G. Forest. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update. Dec,2004;10(6):P 469-485.https://doi.org/10.1093/humupd/dmh047

[11] N Krone, I Wachter, M Stefanidou, et Al.Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood. Clin Endocrinol (Oxf).Oct,2001;55(4).P:523-9.https://doi.org/10.1046/j.1365-2265.2001.01359.x

[12] Wenyu Huang, Mark E Molitch. Evaluation and management of galactorrhea. Am Fam Physician. Jun,2012;85(11) P:1073-80. PMID: 2296879.

[13] Sridevi Atluri,Vijaya Sarathi,et Al. Etiological Profile of Galactorrhea. Indian J Endocrinol Metab.Jul-Aug,2018;22(4) P:489-493.https://doi.org/10.4103/ijem.ijem_89_18

[14] Shlomo Melmed, Felipe F Casanueva, Andrew R Hoffmann, et Al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Feb,2011; 96(2) P:273-88.https://doi.org/10.1210/jc.2010-1692

[15] Jaspreet Chahal, Janet Schlechte. Hyperprolactinemia. Pituitary.Apr,2008;11(2).P:141-6.https://doi.org/10.1007/s11102-008-0107-5